Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
Putting Car-T therapy to work in autoimmune diseases has caught the attention of several biotech and big pharma groups.
Novartis’s Chinook takeout gives a boost to others pursuing this long-researched target, including Vera and Alpine.
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.